Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 8:45 a.m. ET.
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Multiclonics are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus' website, X and LinkedIn.
Multiclonics, Biclonics and Triclonics are registered trademarks of Merus N.V.
CONTACT: Investor and Media Inquiries: Sherri Spear Merus N.V. VP Investor Relations and Corporate Communications 617-821-3246 s.spear@merus.nl Kathleen Farren Merus N.V. IR/Corp Comms 617-230-4165 k.farren@merus.nl
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 8:45 a.m. ET.
荷蘭烏得勒支和馬薩諸塞州劍橋，2024年4月3日（GLOBE NEWSWIRE）——開發創新的全長多特異性抗體的臨床階段腫瘤公司Merus N.V.（納斯達克股票代碼：MRUS）（Biclonics 和 Triclonics），今天宣佈，Merus總裁兼首席執行官比爾·倫德伯格醫學博士將在美國東部時間2024年4月10日星期三上午8點45分參加第23屆尼德姆年度虛擬醫療會議的爐邊談話。
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
演講的網絡直播將同時在公司網站的投資者頁面上播出。存檔的演示文稿也將在活動結束後的限定時間內在那裏提供。
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Multiclonics are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus' website, X and LinkedIn.
關於梅魯斯
Merus 是一家臨床階段的腫瘤學公司，開發創新的全長人雙特異性和三特異性抗體療法，稱爲 Multiclonics。Multiclonics 採用行業標準工藝製造，在臨床前和臨床研究中觀察到其具有與傳統人類單克隆抗體相同的幾種特徵，例如半衰期長和免疫原性低。欲了解更多信息，請訪問梅魯斯的網站、X 和 LinkedIn。
Multiclonics, Biclonics and Triclonics are registered trademarks of Merus N.V.
Multiclonics，Biclonics 和 Triclonics 是 Merus N.V. 的註冊商標
CONTACT: Investor and Media Inquiries: Sherri Spear Merus N.V. VP Investor Relations and Corporate Communications 617-821-3246 s.spear@merus.nl Kathleen Farren Merus N.V. IR/Corp Comms 617-230-4165 k.farren@merus.nl
聯繫人：投資者和媒體查詢：Sherri Spear Merus N.V. 投資者關係和企業傳播副總裁 617-821-3246 s.spear@merus.nl Kathleen Farren Merus N.V. ir/Corp Comms 617-230-4165 k.farren@merus.nl
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧